EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, CRISPR Therapeutics AG's enterprise value is $3,694.8 Mil.
CRISPR Therapeutics AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $370.0 Mil. Therefore, CRISPR Therapeutics AG's EV-to-Revenue for today is 9.99.
The historical rank and industry rank for CRISPR Therapeutics AG's EV-to-Revenue or its related term are showing as below:
CRSP'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.88 Med: 44.44 Max: 23253.66
Current: 9.99
During the past 10 years, the highest EV-to-Revenue of CRISPR Therapeutics AG was 23253.66. The lowest was 1.88. And the median was 44.44.
CRSP's EV-to-Revenue is ranked worse than 55.43% of 1032
companies
in the Biotechnology industry
Industry Median: 7.825
vs CRSP: 9.99
As of today (2024-04-16), CRISPR Therapeutics AG's stock price is $58.72.
CRISPR Therapeutics AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $4.67. Therefore, CRISPR Therapeutics AG's PS Ratio for today is 12.58.
CRISPR Therapeutics AG EV-to-Revenue Historical Data
The historical data trend for CRISPR Therapeutics AG's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
CRISPR Therapeutics AG Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-Revenue
9.71
17,841.97
4.03
3,716.14
9.61
CRISPR Therapeutics AG Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-Revenue
3,716.14
19.19
17.24
12.39
9.61
Competitive Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG EV-to-Revenue Distribution
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's EV-to-Revenue falls into.
CRISPR Therapeutics AG's current Enterprise Value is $3,694.8 Mil.
CRISPR Therapeutics AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $370.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG (NAS:CRSP) EV-to-Revenue Explanation
CRISPR Therapeutics AG's share price for today is $58.72.
CRISPR Therapeutics AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.67.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of CRISPR Therapeutics AG's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
CRISPR Therapeutics AG (CRISPR Therapeutics AG) Business Description
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRSP has been successfully added to your 